Drug Profile
Tavolimab - AstraZeneca
Alternative Names: MEDI-0562; TavolixizumabLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer European Network of Gynaecological Oncological Trial Groups; MedImmune
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action OX40 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer; Solid tumours
Most Recent Events
- 29 May 2020 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
- 14 Feb 2019 Discontinued - Phase-II for Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Denmark (AstraZeneca pipeline, February 2019)
- 14 Feb 2019 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, France, Netherlands (AstraZeneca pipeline, February 2019)